[Synthesis and pharmacokinetic characteristics of 14CH3-polymethacryloyl lupinine--a heparin antagonist].
The quaternary salt of 1-14C-polymetacryloyl lupinine with a specific activity of 1 microCi/mM has been synthesized. It has been shown that intravenous injection of the polymer after heparin administration leads to uneven distribution of the label in the organs. The most intensive reduction of the label was observed in the kidneys. During 10 days, 85% of the label is eliminated from the body with urine and feces (76 and 9% respectively).
D000470:Alkaloids / Q000138:chemical synthesis* / Q000378:metabolism; D000818:Animals; D006493:Heparin / Q000494:pharmacology; D006494:Heparin Antagonists / Q000138:chemical synthesis* / Q000378:metabolism; D007700:Kinetics; D008297:Male; D011109:Polymethacrylic Acids / Q000138:chemical synthesis* / Q000378:metabolism; D051381:Rats; D013034:Sparteine / Q000031:analogs & derivatives; D013997:Time Factors; D014018:Tissue Distribution; D000093843:Quinolizidine Alkaloids
D000470:Alkaloids; D006493:Heparin; D006494:Heparin Antagonists; D011109:Polymethacrylic Acids; D013034:Sparteine; C015971:lupinine; D000093843:Quinolizidine Alkaloids
Sintez i farmakokineticheskie kharakteristiki polimetakriloil-lupinina 14CH3--antagonista geparina.